Condition: Advanced Solid Tumor · Refractory Non-Hodgkin Lymphoma · Sponsor: FBD Biologics Limited
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
This description comes directly from the study's public registry record.
FBD Clinical · +886-2-27921366 · HCB101-101@hanchorbio.com
Always discuss trial participation with your own doctor first.
| Hematology-Oncology Associates of the Treasure Coast | Port Saint Lucie, Florida, United States | Recruiting |
| Carolina BioOncology | Huntersville, North Carolina, United States | Recruiting |
| Greenville Hospital System University Medical Center (ITOR) | Greenville, South Carolina, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Hangzhou First People's Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare | New Taipei City, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05892718